Abnova Taiwan Corp (4133) - Total Liabilities

Latest as of December 2025: NT$70.74 Million TWD ≈ $2.23 Million USD

Based on the latest financial reports, Abnova Taiwan Corp (4133) has total liabilities worth NT$70.74 Million TWD (≈ $2.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Abnova Taiwan Corp - Total Liabilities Trend (2008–2025)

This chart illustrates how Abnova Taiwan Corp's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Abnova Taiwan Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Abnova Taiwan Corp Competitors by Total Liabilities

The table below lists competitors of Abnova Taiwan Corp ranked by their total liabilities.

Company Country Total Liabilities
China Television Co
TW:9928
Taiwan NT$3.11 Billion
Vanfund Urban Investment & Development Co Ltd
SHE:000638
China CN¥153.23 Million
FFI Holdings Ltd
AU:FFI
Australia AU$20.81 Million
Hojeon Ltd
KO:111110
Korea ₩295.10 Billion
HARMONEY CORP. LTD
F:6DR
Germany €843.37 Million
JASTECH Ltd
KQ:090470
Korea ₩42.03 Billion
Thai Textile Industry Public Company Limited
BK:TTI
Thailand ฿595.13 Million
Aeries Technology Inc.
NASDAQ:AERT
USA $44.48 Million

Liability Composition Analysis (2008–2025)

This chart breaks down Abnova Taiwan Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4133 asset base.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 17.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abnova Taiwan Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abnova Taiwan Corp (2008–2025)

The table below shows the annual total liabilities of Abnova Taiwan Corp from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 NT$70.74 Million
≈ $2.23 Million
-22.81%
2024-12-31 NT$91.65 Million
≈ $2.89 Million
+32.01%
2023-12-31 NT$69.42 Million
≈ $2.19 Million
-16.19%
2022-12-31 NT$82.83 Million
≈ $2.61 Million
+16.19%
2021-12-31 NT$71.29 Million
≈ $2.25 Million
-14.61%
2020-12-31 NT$83.49 Million
≈ $2.63 Million
+16.63%
2019-12-31 NT$71.59 Million
≈ $2.26 Million
+5.64%
2018-12-31 NT$67.77 Million
≈ $2.14 Million
-14.28%
2017-12-31 NT$79.05 Million
≈ $2.49 Million
+9.71%
2016-12-31 NT$72.06 Million
≈ $2.27 Million
-12.50%
2015-12-31 NT$82.35 Million
≈ $2.59 Million
+5.37%
2014-12-31 NT$78.15 Million
≈ $2.46 Million
+41.02%
2013-12-31 NT$55.42 Million
≈ $1.75 Million
-12.20%
2012-12-31 NT$63.12 Million
≈ $1.99 Million
-25.31%
2011-12-31 NT$84.51 Million
≈ $2.66 Million
+31.55%
2010-12-31 NT$64.24 Million
≈ $2.02 Million
-32.62%
2009-12-31 NT$95.34 Million
≈ $3.00 Million
-15.41%
2008-12-31 NT$112.71 Million
≈ $3.55 Million
--

About Abnova Taiwan Corp

TW:4133 Taiwan Biotechnology
Market Cap
$40.54 Million
NT$1.29 Billion TWD
Market Cap Rank
#22722 Global
#1412 in Taiwan
Share Price
NT$21.25
Change (1 day)
+0.24%
52-Week Range
NT$20.15 - NT$29.00
All Time High
NT$149.53
About

Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more